S. Chunduru

Statistics

Publications

Citations

H-Index

Active since

1996

Affiliations

University of Arizona Cancer Center(Current)

Idera Pharmaceuticals (United States)

Roswell Park Comprehensive Cancer Center

University of Arizona

The University of Texas MD Anderson Cancer Center

S. Chunduru is an author at University of Arizona Cancer Center specializing in immune checkpoint modulation, metastatic melanoma treatment, and immunotherapy.

Publications per year

1996–2020

Publications

Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate.

H. Trent Spencer, Brian P. Sorrentino, CH Pui et al. · PubMed · 1996 · 32 citations

Medicine, Genetics, Molecular Genetics +12

1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma

Cara Haymaker, Robert H.I. Andtbacka, Douglas B. Johnson et al. · Annals of Oncology · 2020 · 20 citations

Pharmacy, Oncology, Pharmacotherapy +17

Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study

Adi Diab, Cara Haymaker, Chantale Bernatchez et al. · Annals of Oncology · 2018 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract CT134: Tilsotolimod engages the TLR9 pathway to promote antigen presentation and Type-I IFN signaling in solid tumors

Hani M. Babiker, Vivek Subbiah, Asim Ali et al. · Cancer Research · 2020 · 10 citations

Medicine, Immunology, Oncology +15

1–4 of 4